Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
158.5 GBX | 0.00% | +20.99% | -13.15% |
May. 21 | Transcript : Arecor Therapeutics plc - Special Call | |
May. 20 | Arecor Therapeutics' Investigational Insulin Shows Fast Absorption in Early-stage Study | MT |
Sales 2023 | 4.57M 5.82M | Sales 2024 * | 7.49M 9.54M | Capitalization | 48.54M 61.83M |
---|---|---|---|---|---|
Net income 2023 | -8M -10.19M | Net income 2024 * | -5M -6.37M | EV / Sales 2023 | 12.2 x |
Net cash position 2023 * | 6.16M 7.85M | Net cash position 2024 * | 1.46M 1.86M | EV / Sales 2024 * | 6.29 x |
P/E ratio 2023 |
-6.52
x | P/E ratio 2024 * |
-9.06
x | Employees | 51 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 48.52% |
Latest transcript on Arecor Therapeutics plc
1 week | +20.99% | ||
Current month | +16.12% | ||
1 month | +16.12% | ||
3 months | +9.31% | ||
6 months | -14.78% | ||
Current year | -13.15% |
Managers | Title | Age | Since |
---|---|---|---|
Sarah Howell
CEO | Chief Executive Officer | 49 | - |
Susan Lowther
DFI | Director of Finance/CFO | 65 | 18-12-31 |
Jan Jezek
CTO | Chief Tech/Sci/R&D Officer | - | 07-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Alan Smith
BRD | Director/Board Member | 78 | - |
Christine Soden
BRD | Director/Board Member | 66 | 21-04-30 |
Andrew Richards
CHM | Chairman | 64 | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-24 | 158.5 | 0.00% | 38,871 |
24-05-23 | 158.5 | 0.00% | 39,962 |
24-05-22 | 158.5 | 0.00% | 26,985 |
24-05-21 | 158.5 | +8.19% | 106,507 |
24-05-20 | 146.5 | +11.83% | 113,340 |
Delayed Quote London S.E., May 24, 2024 at 11:35 am EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-13.15% | 61.87M | |
+67.53% | 63.85B | |
-0.77% | 41.83B | |
+45.66% | 40.65B | |
-10.72% | 27.12B | |
+13.30% | 26.52B | |
-22.79% | 18.69B | |
+4.70% | 12.73B | |
+24.10% | 12.11B | |
+27.41% | 12.07B |
- Stock Market
- Equities
- AREC Stock